On Tuesday shares of iBio, Inc. (NYSEMKT:IBIO) closed at $0.84. Company’s sales growth for last 5 years was -30.10%. On 6 May, Ibio Inc (NYSEMKT:IBIO) declared the issue of a new U.S. patent expanding the company’s iBioModulator™ thermostable immunomodulator protein portfolio. The new patent, serial number 9,012,199, is entitled “Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides.” The fundamental composition of matter claims grant iBio important exclusivity over new, modified carrier molecules derived from the company’s proprietary iBioModulator™ thermostable immunomodulator protein system and their use with one or more target proteins or antigens.
Aeterna Zentaris Inc. (NASDAQ:AEZS) in last trading activity fell -9.48% to close at $0.43. Company weekly performance is -19.49% while its quarterly performance stands at -19.79%. Aeterna Zentaris Inc. (NASDAQ:AEZS) is -72.40% away from its 52 week high. Aeterna Zentaris Inc. (NASDAQ:AEZS) and EMD Serono, Inc. on 7 May announced the finalization of a promotional services agreement that will allow Aeterna Zentaris to promote Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the United States. Saizen® is a recombinant human Growth Hormone (r-hGH) registered in the U.S. for the treatment of growth hormone deficiency (GHD) in children and adults.
On Tuesday shares of Embotelladora Andina S.A. (NYSE:AKO-B) closed at $20.30. Zacks restated their hold rating on shares of Embotelladora Andina SA (NYSE:AKO.B) in a research note issued to investors on 1 May.
International Business Machines Corporation (NYSE:IBM) in last trading activity fell -0.33% to close at $170.55. Company weekly performance is -0.72% while its quarterly performance stands at 8.38%. International Business Machines Corporation (NYSE:IBM) is -10.76% away from its 52 week high. International Business Machines Corporation (NYSE:IBM) said that a new contract with New Zealand’s Ministry of Health is another step in its success in driving strong cloud momentum in the Australia and New Zealand markets.
On last trading day Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) moved up 0.47% to close at $2.12. Its volatility for the week is 4.47% while volatility for the month is 4.57%. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) monthly performance is 7.61%. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) on 7 May, reported financial results for the quarter ended March 31, 2015. Total revenues for the first quarter of 2015 were $4.4 million compared to $6.7 million for the first quarter of 2014. The decrease resulted primarily from a decrease of $1.8 million of products sold in Brazil and a decrease of $597,000 of products we delivered at cost to Pfizer Inc. under our license agreement.